EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and novel infusion therapies for patients with Parkinson's disease

Angelo Antonini iD, Valentina D'Onofrio iD, Andrea Guerra iD

Journal of Neural Transmission · 2023

DOI: 10.1007/s00702-023-02693-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, 2023. Verfasst von Angelo Antonini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Via Giustini…. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced Parkinson’s disease is characterized by periods of poor mobility, dyskinesia and progressive decline in functional independence of the affected person despite the manipulation of levodopa doses and the introduction of supplemental therapies such as catechol-O-methyl transferase inhibitors, monoamine oxidase-B inhibitors and dopamine agonists. The implementation of drug delivery systems allows to bypass problems related to irregular and often unpredictable intestinal absorption of oral levodopa, which significantly affects its bioavailability and contributes to the development and persistence of motor complications. Subcutaneous apomorphine and levodopa/carbidopa jejunal infusion systems have been available for many years and their efficacy is confirmed by randomized studies and long-term experience in many centers worldwide. Recently, a new formulation of levodopa/carbidopa infusion gel that includes the catechol-O-methyl transferase inhibitor Entacapone has been introduced to the market. The use of entacapone allows to reduce total daily dose of administered levodopa. Two different soluble formulations of levodopa/carbidopa (ND0612 and ABBV-951) have completed clinical development, and both can ensure subcutaneous delivery by a portable pump infusion system. ABBV-951 uses a foslevodopa/foscarbidopa formulation, both prodrugs to improve absorption and tolerability. Both systems provide effective improvement of motor complications and are likely to expand the therapeutic options in advanced patients. Future efforts should focus on the earlier detection of patients who are candidates for device-aided therapies, increasing appropriate referral and broadening the availability of these treatments globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansLevodopaCarbidopaAntiparkinson AgentsCatechol O-MethyltransferaseCatecholsDopamine AgonistsDrug CombinationsNitriles

Stichwörter der Autor:innen

ApomorphineDevice-aided therapiesInfusion therapiesLevodopa/carbidopa intestinal gelParkinson’s diseaseSubcutaneous levodopa

Substanzen

LevodopaCarbidopaAntiparkinson AgentsCatechol O-MethyltransferaseCatecholsDopamine AgonistsDrug CombinationsentacaponeNitriles

Autor:innen und Institutionen

  • Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Via Giustiniani 3, 35121, Padua, Italy. angelo.antonini@unipd.it.
  • Padova Neuroscience Center (PNC), University of Padua, Padua, Italy. angelo.antonini@unipd.it.
  • Padova Neuroscience Center (PNC), University of Padua, Padua, Italy.
  • Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Via Giustiniani 3, 35121, Padua, Italy.

ORCID-Profile: Angelo Antonini, Valentina D'Onofrio, Andrea Guerra

Förderung

  • Università degli Studi di Padova

Zitieren

APA

Antonini, A., D'Onofrio, V., & Guerra, A. (2023). Current and novel infusion therapies for patients with Parkinson's disease. Journal of Neural Transmission. https://doi.org/10.1007/s00702-023-02693-8

Vancouver

Antonini A, D'Onofrio V, Guerra A. Current and novel infusion therapies for patients with Parkinson's disease. Journal of Neural Transmission. 2023. doi:10.1007/s00702-023-02693-8

BibTeX
@article{Antonini2023,
  author = {Antonini, Angelo and D'Onofrio, Valentina and Guerra, Andrea},
  title = {Current and novel infusion therapies for patients with Parkinson's disease},
  journal = {Journal of Neural Transmission},
  year = {2023},
  doi = {10.1007/s00702-023-02693-8}
}
Kostenlos starten →